[go: up one dir, main page]

NO982588D0 - FremgangsmÕte for diagnose og behandling av plate epizelkarsinom - Google Patents

FremgangsmÕte for diagnose og behandling av plate epizelkarsinom

Info

Publication number
NO982588D0
NO982588D0 NO982588A NO982588A NO982588D0 NO 982588 D0 NO982588 D0 NO 982588D0 NO 982588 A NO982588 A NO 982588A NO 982588 A NO982588 A NO 982588A NO 982588 D0 NO982588 D0 NO 982588D0
Authority
NO
Norway
Prior art keywords
diagnosis
procedure
treatment
cell carcinoma
squamous cell
Prior art date
Application number
NO982588A
Other languages
English (en)
Other versions
NO319903B1 (no
NO982588L (no
Inventor
Karl-Heinz Heider
Guenter Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Original Assignee
Boehringer Ingelheim Int
Karlsruhe Forschzent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim Int, Karlsruhe Forschzent filed Critical Boehringer Ingelheim Int
Publication of NO982588D0 publication Critical patent/NO982588D0/no
Publication of NO982588L publication Critical patent/NO982588L/no
Publication of NO319903B1 publication Critical patent/NO319903B1/no

Links

Classifications

    • G01N33/575
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585CD44
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19982588A 1995-12-06 1998-06-05 Anvendelse av et antistoffmolekyl for fremstilling av et farmasoytisk preparat for behandling av plateepitelkarsinom. NO319903B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17
PCT/EP1996/005448 WO1997021104A1 (de) 1995-12-06 1996-12-05 Verfahren zur diagnose und therapie von plattenepithelkarzinomen

Publications (3)

Publication Number Publication Date
NO982588D0 true NO982588D0 (no) 1998-06-05
NO982588L NO982588L (no) 1998-08-05
NO319903B1 NO319903B1 (no) 2005-09-26

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19982588A NO319903B1 (no) 1995-12-06 1998-06-05 Anvendelse av et antistoffmolekyl for fremstilling av et farmasoytisk preparat for behandling av plateepitelkarsinom.

Country Status (25)

Country Link
EP (1) EP0865609B1 (no)
JP (1) JP2000502067A (no)
KR (1) KR100473824B1 (no)
CN (1) CN1151377C (no)
AR (1) AR004360A1 (no)
AT (1) ATE235056T1 (no)
AU (1) AU726704B2 (no)
BG (1) BG62985B1 (no)
BR (1) BR9611901A (no)
CA (1) CA2239709A1 (no)
CO (1) CO4520233A1 (no)
CZ (1) CZ174198A3 (no)
DE (1) DE59610248D1 (no)
DK (1) DK0865609T3 (no)
EE (1) EE03783B1 (no)
ES (1) ES2190484T3 (no)
MX (1) MX9804459A (no)
NO (1) NO319903B1 (no)
NZ (1) NZ324314A (no)
PL (1) PL184521B1 (no)
PT (1) PT865609E (no)
SK (1) SK284378B6 (no)
TR (1) TR199801027T2 (no)
UY (1) UY24389A1 (no)
WO (1) WO1997021104A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
CN1541226A (zh) * 2001-05-18 2004-10-27 ���ָ��Ӣ��ķ�������Ϲ�˾ CD44v6特异性的抗体
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
BR112012019475A8 (pt) * 2010-02-04 2017-12-26 Hoffmann La Roche uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
US9218450B2 (en) * 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
CN112105643B (zh) * 2018-02-22 2023-09-26 普众发现医药科技(上海)有限公司 治疗性抗体及其应用
CN119451984A (zh) 2022-05-25 2025-02-14 阿基拉姆治疗有限公司 抗cd44v6抗体及其用于治疗cd44v6过表达癌症的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678487B2 (en) * 1993-06-18 1997-05-29 Oy Biotie Therapies Ltd Compositions and diagnostic methods using monoclonal antibodies against CD44v6
EP0767380A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Zervixkarzinomen
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Also Published As

Publication number Publication date
BG102513A (en) 1999-02-26
TR199801027T2 (xx) 1998-10-21
EP0865609B1 (de) 2003-03-19
EE03783B1 (et) 2002-06-17
BR9611901A (pt) 1999-03-02
AU1177397A (en) 1997-06-27
SK73698A3 (en) 1999-01-11
MX9804459A (es) 1998-09-30
DK0865609T3 (da) 2003-06-23
CO4520233A1 (es) 1997-10-15
NO319903B1 (no) 2005-09-26
CA2239709A1 (en) 1997-06-12
WO1997021104A1 (de) 1997-06-12
AR004360A1 (es) 1998-11-04
EE9800164A (et) 1998-12-15
UY24389A1 (es) 2001-10-25
HK1011560A1 (en) 1999-07-16
ES2190484T3 (es) 2003-08-01
EP0865609A1 (de) 1998-09-23
PL184521B1 (pl) 2002-11-29
NZ324314A (en) 2000-02-28
KR100473824B1 (ko) 2005-09-30
CN1151377C (zh) 2004-05-26
BG62985B1 (bg) 2000-12-29
NO982588L (no) 1998-08-05
SK284378B6 (sk) 2005-02-04
ATE235056T1 (de) 2003-04-15
CZ174198A3 (cs) 1999-02-17
CN1207811A (zh) 1999-02-10
AU726704B2 (en) 2000-11-16
DE59610248D1 (de) 2003-04-24
JP2000502067A (ja) 2000-02-22
KR19990071952A (ko) 1999-09-27
PL327066A1 (en) 1998-11-23
PT865609E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
NO982588D0 (no) FremgangsmÕte for diagnose og behandling av plate epizelkarsinom
DE60029812D1 (de) Diagnose von zellenproliferation sowie screeningverfahren für deren modulatore
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
ATE361935T1 (de) Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens
DE69433564D1 (de) Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
DE60033555D1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
DE69737788D1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
ATE552270T1 (de) Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren
TR200001313T2 (tr) Protein etkileşimlerini ve fonksiyonel ilişkileri kaydeden tarama sistemleri
ATE403743T1 (de) Genetische veränderungen, die mit lungencarzinomen korrelieren
DE69507470D1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
DE69735436D1 (de) Methode zum nachweis von zell-apoptose
ATE347561T1 (de) Behandlung von entzündungskrankheiten
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE60038894D1 (de) Screeningverfahren für geeignete wirkstoffe
DE69021742D1 (de) Verfahren zum Nachweis von kleinzelligem Carzinom und die Verwendung von Sequenzen, die Acylpeptid-Hydrolase codieren, für diesen zweck.
ATE114048T1 (de) Mittel für immunchemische tests, carboxylgruppenhaltige polymere enthaltend.
WO2000005374A3 (en) Molecules associated with cell proliferation
CA2415364A1 (en) Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
DE69734890D1 (de) Rdgb-proteine
DE69931644D1 (de) Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen
ATE546544T1 (de) Verfahren zur diagnose und behandlung von lungenkrebs
NO970130D0 (no) Oligomere bærermolekyler med definerte, innebygde markörgrupper og haptener
AU4121997A (en) Method for sorting antifungal molecules acting on the glucanosyltransferase activity
HUP9904404A1 (hu) Eljárás laphám-karcinómák diagnosztizálására és kezelésére